Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Tenax Therapeutics, Inc.

Market Cap 626M 547M 506M 472M 886M 59.15B 893M 6.01B 2.34B 29.08B 2.35B 2.3B 101B P/E 2026 *
-8.56x
P/E 2027 * -8.79x
Enterprise Value 626M 547M 506M 472M 886M 59.15B 893M 6.01B 2.34B 29.08B 2.35B 2.3B 101B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.88%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Tenax Therapeutics, Inc.

1 day+4.78%
1 week+13.15%
Current month+8.00%
1 month+7.01%
3 months-10.16%
6 months+7.19%
Current year+5.17%
1 week 11.26
Extreme 11.26
12.86
1 month 10.25
Extreme 10.25
12.86
Current year 10.25
Extreme 10.25
18.38
1 year 5.62
Extreme 5.616
18.38
3 years 2.77
Extreme 2.77
61.2
5 years 2.77
Extreme 2.77
3,625.92
10 years 2.77
Extreme 2.77
88,640
Manager TitleAgeSince
Chief Executive Officer 52 14/07/2021
Director of Finance/CFO 58 11/05/2026
Chief Tech/Sci/R&D Officer - 21/01/2025
Director TitleAgeSince
Chairman 67 01/06/2021
Director/Board Member 76 25/02/2021
Director/Board Member 69 25/02/2021
Date Insider Type Main position Quantity % Market Cap.
05-11Free

Chief Financial Officer

460,000 2.6748%
05-11Other

Chief Financial Officer

0 0%
01-30Other

Controller/Auditor

50,000 0.8008%
Change 5-day change 1-year change 3-year change Capi.($)
+4.78%+13.15%+128.11%-48.14% 626M
+3.34%+4.53%-7.88%-2.45% 43.24B
+2.74%+8.78%+325.40%+567.44% 35.25B
+1.30%+3.72%+6.30%+52.69% 30.22B
+1.15%-5.08%+9.60%-20.55% 28.01B
-1.06%-3.71%+9.08%+19.56% 24.08B
+2.34%+0.77% - - 14.16B
+0.74%-0.15%+49.34%+106.33% 13.01B
+2.68%+3.92%+9.51%+15.20% 12.7B
+1.02%+4.76%+103.26%+93.16% 12.54B
Average +1.92%+0.94%+70.30%+87.03% 21.38B
Weighted average by Cap. +1.78%-0.16%+69.84%+120.69%

Financials

2026 *2027 *
Net sales - -
Net income -79.71M -69.65M -64.42M -60.13M -113M -7.53B -114M -766M -298M -3.7B -299M -293M -12.87B -93.97M -82.11M -75.95M -70.89M -133M -8.88B -134M -903M -351M -4.37B -353M -345M -15.17B
Net Debt - -
Logo Tenax Therapeutics, Inc.
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
Employees
15
Date Price Change Volume
23/06/26 $12.83 +4.73% 141,756
22/06/26 $12.25 +2.08% 877,058
18/06/26 $12.00 +1.10% 2,691,091
17/06/26 $11.87 +4.77% 1,280,545
16/06/26 $11.33 -1.90% 795,067
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
12.25USD
Average target price
33.88USD
Spread / Average Target
+176.53%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TENX Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!